Justin Kirkland is a longevity medicine expert who caters his educational expertise to healthcare providers. He holds a BS in Agronomy and an MS in Biology, and attended medical school in Belize at the Central American Health Sciences University. He was awarded a U.S. patent for the improved synthesis of the ergoline BOL-148: useful in treating cluster headaches and has many other filed patents. He has years of experience in pharmaceutical drug development, patent filing, and pharmacology, and has worked as one of the industry’s leading peptide chemists. Justin is known globally for producing clinical trial materials in Canada for both the medical use of psilocybin mushroom micro-dosing for the treatment of depression and MDMA for PTSD studies. As the founding scientist and CEO of Nutraneeds, a nutraceutical company that provides key products for medical practitioners, he has developed products, manufactured unique formulations, and developed safe and effective supplements endorsed by the medical community as invaluable for their patients. Justin is currently pursuing future drug development research in conjunction with The University of Miami Miller School of Medicine, Molecular Biology, and Biochemistry Ph.D. program.